Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Neurodegenerative Diseases Drug market report explains the definition, types, applications, major countries, and major players of the Neurodegenerative Diseases Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Teva Pharmaceuticals
Pfizer
Mitsubishi Tanabe Pharma America
Sanofi
Roche
UCB SA
Biogen
ACADIA Pharmaceuticals Inc
Novartis
Orion Pharma Ltd
Lundbeck Pharmaceuticals Italy SpA
By Type:
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal
By End-User:
Multiple Sclerosis
Parkinson?s Disease
Alzheimer?s Disease
Spinal Muscular Atrophy (SMA)
Others
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Neurodegenerative Diseases Drug Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Neurodegenerative Diseases Drug Outlook to 2028- Original Forecasts
-
2.2 Neurodegenerative Diseases Drug Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Neurodegenerative Diseases Drug Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Neurodegenerative Diseases Drug Market- Recent Developments
-
6.1 Neurodegenerative Diseases Drug Market News and Developments
-
6.2 Neurodegenerative Diseases Drug Market Deals Landscape
7 Neurodegenerative Diseases Drug Raw Materials and Cost Structure Analysis
-
7.1 Neurodegenerative Diseases Drug Key Raw Materials
-
7.2 Neurodegenerative Diseases Drug Price Trend of Key Raw Materials
-
7.3 Neurodegenerative Diseases Drug Key Suppliers of Raw Materials
-
7.4 Neurodegenerative Diseases Drug Market Concentration Rate of Raw Materials
-
7.5 Neurodegenerative Diseases Drug Cost Structure Analysis
-
7.5.1 Neurodegenerative Diseases Drug Raw Materials Analysis
-
7.5.2 Neurodegenerative Diseases Drug Labor Cost Analysis
-
7.5.3 Neurodegenerative Diseases Drug Manufacturing Expenses Analysis
8 Global Neurodegenerative Diseases Drug Import and Export Analysis (Top 10 Countries)
-
8.1 Global Neurodegenerative Diseases Drug Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Neurodegenerative Diseases Drug Export by Region (Top 10 Countries) (2017-2028)
9 Global Neurodegenerative Diseases Drug Market Outlook by Types and Applications to 2022
-
9.1 Global Neurodegenerative Diseases Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global By Drug Class Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Immunomodulator Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Interferons Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.5 Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
9.1.6 Global Others Consumption and Growth Rate (2017-2022)
-
9.1.7 Global By Route of Administration Consumption and Growth Rate (2017-2022)
-
9.1.8 Global Oral Consumption and Growth Rate (2017-2022)
-
9.1.9 Global Injection Consumption and Growth Rate (2017-2022)
-
9.1.10 Global Transdermal Consumption and Growth Rate (2017-2022)
-
9.2 Global Neurodegenerative Diseases Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Parkinson?s Disease Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Alzheimer?s Disease Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Others Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Neurodegenerative Diseases Drug Market Analysis and Outlook till 2022
-
10.1 Global Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.2.2 Canada Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.2.3 Mexico Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.2 UK Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.3 Spain Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.4 Belgium Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.5 France Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.6 Italy Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.7 Denmark Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.8 Finland Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.9 Norway Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.10 Sweden Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.11 Poland Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.12 Russia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.3.13 Turkey Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.2 Japan Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.3 India Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.4 South Korea Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.5 Pakistan Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.6 Bangladesh Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.7 Indonesia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.8 Thailand Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.9 Singapore Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.10 Malaysia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.11 Philippines Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.4.12 Vietnam Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.2 Colombia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.3 Chile Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.4 Argentina Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.5 Venezuela Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.6 Peru Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.7 Puerto Rico Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.5.8 Ecuador Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6.2 Kuwait Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6.3 Oman Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6.4 Qatar Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6.5 Saudi Arabia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.6.6 United Arab Emirates Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.7.2 South Africa Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.7.3 Egypt Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.7.4 Algeria Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Neurodegenerative Diseases Drug Consumption (2017-2022)
-
10.8.2 New Zealand Neurodegenerative Diseases Drug Consumption (2017-2022)
11 Global Neurodegenerative Diseases Drug Competitive Analysis
-
11.1 Teva Pharmaceuticals
-
11.1.1 Teva Pharmaceuticals Company Details
-
11.1.2 Teva Pharmaceuticals Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.1.4 Teva Pharmaceuticals Neurodegenerative Diseases Drug Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 Pfizer
-
11.2.1 Pfizer Company Details
-
11.2.2 Pfizer Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 Pfizer Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.2.4 Pfizer Neurodegenerative Diseases Drug Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Mitsubishi Tanabe Pharma America
-
11.3.1 Mitsubishi Tanabe Pharma America Company Details
-
11.3.2 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.3.4 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Sanofi
-
11.4.1 Sanofi Company Details
-
11.4.2 Sanofi Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Sanofi Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.4.4 Sanofi Neurodegenerative Diseases Drug Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Roche
-
11.5.1 Roche Company Details
-
11.5.2 Roche Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Roche Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.5.4 Roche Neurodegenerative Diseases Drug Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 UCB SA
-
11.6.1 UCB SA Company Details
-
11.6.2 UCB SA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 UCB SA Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.6.4 UCB SA Neurodegenerative Diseases Drug Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Biogen
-
11.7.1 Biogen Company Details
-
11.7.2 Biogen Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Biogen Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.7.4 Biogen Neurodegenerative Diseases Drug Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 ACADIA Pharmaceuticals Inc
-
11.8.1 ACADIA Pharmaceuticals Inc Company Details
-
11.8.2 ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.8.4 ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Novartis
-
11.9.1 Novartis Company Details
-
11.9.2 Novartis Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Novartis Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.9.4 Novartis Neurodegenerative Diseases Drug Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Orion Pharma Ltd
-
11.10.1 Orion Pharma Ltd Company Details
-
11.10.2 Orion Pharma Ltd Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.10.4 Orion Pharma Ltd Neurodegenerative Diseases Drug Product Portfolio
-
11.10.5 Recent Research and Development Strategies
-
11.11 Lundbeck Pharmaceuticals Italy SpA
-
11.11.1 Lundbeck Pharmaceuticals Italy SpA Company Details
-
11.11.2 Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
11.11.3 Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Main Business and Markets Served
-
11.11.4 Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Product Portfolio
-
11.11.5 Recent Research and Development Strategies
12 Global Neurodegenerative Diseases Drug Market Outlook by Types and Applications to 2028
-
12.1 Global Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global Immunomodulator Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
12.1.5 Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
12.1.6 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.1.7 Global By Route of Administration Consumption Forecast and Growth Rate (2022-2028)
-
12.1.8 Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
12.1.9 Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
12.1.10 Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Parkinson?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.3 Global Alzheimer?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
12.2.4 Global Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)
-
12.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Neurodegenerative Diseases Drug Market Analysis and Outlook to 2028
-
13.1 Global Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.2.2 Canada Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.2.3 Mexico Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.2 UK Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.3 Spain Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.4 Belgium Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.5 France Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.6 Italy Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.7 Denmark Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.8 Finland Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.9 Norway Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.10 Sweden Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.11 Poland Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.12 Russia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.3.13 Turkey Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.2 Japan Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.3 India Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.4 South Korea Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.8 Thailand Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.9 Singapore Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.11 Philippines Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.2 Colombia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.3 Chile Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.4 Argentina Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.6 Peru Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6.3 Oman Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6.4 Qatar Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.7.2 South Africa Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.7.3 Egypt Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.7.4 Algeria Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Neurodegenerative Diseases Drug Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Neurodegenerative Diseases Drug
-
Figure of Neurodegenerative Diseases Drug Picture
-
Table Global Neurodegenerative Diseases Drug Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Neurodegenerative Diseases Drug Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global By Drug Class Consumption and Growth Rate (2017-2022)
-
Figure Global Immunomodulator Consumption and Growth Rate (2017-2022)
-
Figure Global Interferons Consumption and Growth Rate (2017-2022)
-
Figure Global Decarboxylase Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Dopamine Agonists Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global By Route of Administration Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Consumption and Growth Rate (2017-2022)
-
Figure Global Injection Consumption and Growth Rate (2017-2022)
-
Figure Global Transdermal Consumption and Growth Rate (2017-2022)
-
Figure Global Multiple Sclerosis Consumption and Growth Rate (2017-2022)
-
Figure Global Parkinson?s Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Alzheimer?s Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Spinal Muscular Atrophy (SMA) Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Table North America Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure United States Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Canada Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Mexico Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table Europe Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure Germany Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure UK Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Spain Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Belgium Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure France Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Italy Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Denmark Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Finland Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Norway Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Sweden Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Poland Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Russia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Turkey Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table APAC Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure China Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure India Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Thailand Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Singapore Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Philippines Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table South America Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure Brazil Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Colombia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Chile Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Argentina Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Peru Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table GCC Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure Bahrain Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Oman Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Qatar Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table Africa Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure Nigeria Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure South Africa Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Egypt Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure Algeria Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table Oceania Neurodegenerative Diseases Drug Consumption by Country (2017-2022)
-
Figure Australia Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Neurodegenerative Diseases Drug Consumption and Growth Rate (2017-2022)
-
Table Teva Pharmaceuticals Company Details
-
Table Teva Pharmaceuticals Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceuticals Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Teva Pharmaceuticals Neurodegenerative Diseases Drug Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Pfizer Neurodegenerative Diseases Drug Product Portfolio
-
Table Mitsubishi Tanabe Pharma America Company Details
-
Table Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Sanofi Neurodegenerative Diseases Drug Product Portfolio
-
Table Roche Company Details
-
Table Roche Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Roche Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Roche Neurodegenerative Diseases Drug Product Portfolio
-
Table UCB SA Company Details
-
Table UCB SA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table UCB SA Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table UCB SA Neurodegenerative Diseases Drug Product Portfolio
-
Table Biogen Company Details
-
Table Biogen Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Biogen Neurodegenerative Diseases Drug Product Portfolio
-
Table ACADIA Pharmaceuticals Inc Company Details
-
Table ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table ACADIA Pharmaceuticals Inc Neurodegenerative Diseases Drug Product Portfolio
-
Table Novartis Company Details
-
Table Novartis Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Novartis Neurodegenerative Diseases Drug Product Portfolio
-
Table Orion Pharma Ltd Company Details
-
Table Orion Pharma Ltd Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Orion Pharma Ltd Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Orion Pharma Ltd Neurodegenerative Diseases Drug Product Portfolio
-
Table Lundbeck Pharmaceuticals Italy SpA Company Details
-
Table Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Main Business and Markets Served
-
Table Lundbeck Pharmaceuticals Italy SpA Neurodegenerative Diseases Drug Product Portfolio
-
Figure Global By Drug Class Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Immunomodulator Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Interferons Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Decarboxylase Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Dopamine Agonists Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global By Route of Administration Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Injection Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Transdermal Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Multiple Sclerosis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Parkinson?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Alzheimer?s Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Spinal Muscular Atrophy (SMA) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Table North America Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure United States Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure Germany Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure China Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure Brazil Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Neurodegenerative Diseases Drug Consumption Forecast by Country (2022-2028)
-
Figure Australia Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Neurodegenerative Diseases Drug Consumption Forecast and Growth Rate (2022-2028)
-
